Analysis of regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC)

被引：1

作者：

Tannir, N. ^{[1
]}

Powles, T. ^{[2
]}

Motzer, R. J. ^{[3
]}

Rolland, F. ^{[4
]}

Gravis, G. ^{[5
]}

Staehler, M. ^{[6
]}

Rink, M. ^{[7
]}

Retz, M. ^{[8
]}

Csoszi, T. ^{[9
]}

McCaffrey, J. ^{[10
]}

De Giorgi, U. ^{[11
]}

Caserta, C. ^{[12
]}

Cheporov, S. ^{[13
]}

Esteban Gonzalez, E. ^{[14
]}

Duran, I. ^{[15
]}

Larkin, J. G. ^{[16
]}

Berg, W. ^{[17
]}

Clary, D. ^{[17
]}

Escudier, B. ^{[18
]}

Choueiri, T. K. ^{[19
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA

[2] Queen Mary Univ London, Barts Canc Inst, Expt Canc Med, London, England

[3] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[4] ICO Inst Cancerol Ouest Rene Gauducheau, Med Oncol, St Herblain, France

[5] Inst Paoli Calmettes, Med Outpatient, Urol, Marseille, France

[6] Maximilians Univ Munchen, Klinikum Ludwig, Urol, Munich, Germany

[7] Univ Med Ctr Hamburg Eppendorf, Urol, Hamburg, Germany

[8] Klinikum Rechts Isar Tech, Urol, Munich, Germany

[9] Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Med Oncol & Hematol, Szolnok, Hungary

[10] Mater Private Hosp, Med Oncol, Oncol, Dublin, Ireland

[11] Ist Sci Romagnolo Studio & Cura Tumori, Med Oncol, Meldola, Italy

[12] Azienda Osped Sta Maria, Oncol, Terni, Italy

[13] Reg Clin Oncol Hosp, Clin Oncol, Yaroslavl, Russia

[14] Clinica, Oncol, Edificio Consultas Externas, Oviedo, Spain

[15] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain

[16] Royal Marsden Hosp NHS Fdn Trust, Med Oncol, London, England

[17] Exelixis Inc, Med Affairs, San Francisco, CA USA

[18] Inst Gustave Roussy, Immunotherapy & Innovat Therapy Unit, Villejuif, France

[19] Brigham & Womens Hosp, Dana Farber Canc Inst, Genitourinary Oncol, 75 Francis St, Boston, MA 02115 USA

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw373.45

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

818P

引用

页数：1

共 50 条

[41] Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC)
Powles, Thomas
Motzer, Robert J.
Escudier, Bernard J.
Pal, Sumanta K.
Kollmannsberger, Christian K.
Pikiel, Joanna
Gurney, Howard
Rha, Sun Young
Park, Se Hoon
Geertsen, Poul F.
Gross-Goupil, Marine
Grande, Enrique
Suarez, Cristina
Arroyo, Alan M.
Dean, Mark
George, Daniel
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[42] CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC)
Motzer, Robert J.
Escudier, Bernard
Mcdermott, David F.
George, Saby
Hammers, Hans J.
Srinivas, Sandhya
Tykodi, Scott S.
Sosman, Jeffrey A.
Procopio, Giuseppe
Plimack, Elizabeth R.
Castellano, Daniel
Gurney, Howard
Donskov, Frede
Bono, Petri
Wagstaff, John
Gauler, Thomas C.
Ueda, Takeshi
Xu, Li-An
Waxman, Ian M.
Sharma, Padmanee
BJU INTERNATIONAL, 2015, 116 : 17 - 17
[43] Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a firstline treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Motzer, Robert J.
Porta, Camillo
Eto, Masatoshi
Powles, Thomas
Grunwald, Viktor
Hutson, Thomas E.
Alekseev, Boris
Rha, Sun Young
Kopyltsov, Evgeny
Mendez Vidal, Maria Jose
Hong, Sung-Hoo
Kapoor, Anil
Gordoa, Teresa Alonso
Goh, Jeffrey C.
Merchan, Jaime R.
Smith, Alan D.
Mody, Kalgi
Perini, Rodolfo F.
Xing Dongyuan
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[44] CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
Motzer, Robert J.
Sharma, Padmanee
McDermott, David F.
George, Saby
Hammers, Hans J.
Srinivas, Sandhya
Tykodi, Scott S.
Sosman, Jeffrey Alan
Procopio, Giuseppe
Plimack, Elizabeth R.
Castellano, Daniel E.
Gurney, Howard
Donskov, Frede
Bono, Petri
Wagstaff, John
Gauler, Thomas Christoph
Ueda, Takeshi
Zhao, Huanyu
Waxman, Ian M.
Escudier, Bernard
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
[45] Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)
Whorf, R. C.
Hainsworth, J. D.
Spigel, D. R.
Yardley, D. A.
Burris, H. A., III
Waterhouse, D. M.
Vazquez, E. R.
Greco, F. A.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[46] Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).
McGregor, Bradley Alexander
Huang, Jiaming
Xie, Wanling
Xu, Wenxin
Bilen, Mehmet Asim
Braun, David A.
Zhang, Tian
McKay, Rana R.
McDermott, David F.
Hammers, Hans J.
Choueiri, Toni K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Phase II study of sequential first-line pazopanib (PAZ) followed by everolimus (EVE) in patients (pts) with advanced or metastatic renal cell carcinoma (RCC) (CATChEz Study).
de Souza, Paul L.
Wong, Shirley
Sewak, Sanjeev
Kotasek, Dusan
Keam, Bhumsuk
Chung, Jinsoo
Erbeck, Noelle
Han, Jackie
Dezzani, Luca
Ahmad, Qasim
Mainwaring, Paul N.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[48] Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.
Chanza, Nieves Martinez
Bosse, Dominick
Bilen, Mehmet Asim
Geynisman, Daniel M.
Balakrishnan, Archana
Jain, Rohit K.
Bowman, I. Alex
Zakharia, Yousef
Narayan, Vivek
Beuselinck, Benoit
Agarwal, Neeraj
McKay, Rana R.
Hsu, Joann
Shah, Sumit
Tripathi, Abhishek
Lam, Elaine Tat
Rose, Tracy Lynn
Carneiro, Benedito A.
Vogelzang, Nicholas J.
Harshman, Lauren Christine
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[49] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Denize, Thomas
Farah, Subrina
Cimadamore, Alessia
Flaifel, Abdallah
Walton, Emily
Sticco-Ivins, Maura A.
Labaki, Chris
Braun, David A.
Sun, Maxine
Wang, Evelyn
Xie, Wanling
Choueiri, Toni K.
Signoretti, Sabina
CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
[50] Population pharmacokinetic (PopPK) and exposure-response (ER) modeling of cabozantinib (C) in patients (pts) with renal cell carcinoma (RCC) in the phase 3 METEOR study.
Lacy, Steven
Hutmacher, Matthew M.
Yang, Bei
Motzer, Robert J.
Escudier, Bernard J.
Powles, Thomas
Choueiri, Toni K.
Miles, Dale
Nielsen, Jace
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

← 1 2 3 4 5 →